RxDoctor Payments Data

Sarah Uddin

Adult Medicine · Oakland, NJNPI 1104262948

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by AstraZeneca at 37.6% of the total. Reporting peaked in 2020 at $276 and has fallen 54.3% since, to $126 in 2021.

$520in general payments, 2019–2025

Across 31 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$195
  • Novo Nordisk$179
  • Amarin Pharma, Inc.$55
  • Novartis$42
  • Regeneron Healthcare Solutions, Inc.$37
  • Kowa Pharmaceuticals America, Inc.$11

What the payments were for

  • Food & beverage$520100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$520 in reported general payments places this provider in the 60th percentile of 48 adult medicine providers in New Jersey.

See all adult medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$89,148
Medicare patients
228
Services billed
1,119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide21$19,946
MounjaroTirzepatide17$19,309
EliquisApixaban25$16,206
JanumetSitagliptin Phos/Metformin Hcl17$8,671
TradjentaLinagliptin13$6,037
Atorvastatin Calcium162$1,968
Levothyroxine Sodium148$1,855
Simvastatin85$965
Rosuvastatin Calcium80$962
Mirtazapine23$959
Valsartan50$957
Escitalopram Oxalate84$816
Amlodipine Besylate128$806
Armour ThyroidThyroid,pork15$601
Ipratropium Bromide30$581

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$179$19,94621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 48 adult medicine providers in New Jersey.

Other adult medicine in Oakland

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →